Intravitreal Injection of Bevacizumab for Glioblastoma Multiforme Treatment: a Case Report

Tumor angiogenesis depends on Vascular Endothelial Growth Factor (VEGF) secretion to promote neovascularization from existing vessels. In order to block this tumor-induced neo-angiogenesis, anti-VEGF antibody (bevacizumab) has been developed to bind and neutralize all biologically active iso-forms of VEGF). Bevacizumab (BV) is approved by Food and Drug Administration (FDA) for the treatment of recurrent Glioblastoma Multiforme (GBM), resulting in good tumor stability, in association with temozolomide (TMZ). GBM is characterized by a poor prognosis and a median overall survival (OS) of 8- 16 months. There is currently no standard treatment options or approaches other than standard chemoradiation for patients with multifocal or single-lesion unresectable GBM. In the current study, we present a case of tumor response after intravitreal injection of BV in a patient who progressed to chemoradiation with TMZ. This case report shows that the blockade of neo-angiogenesis by BV was able to induce tumor reduction and response to TMZ.